Cargando…
Sanger Sequencing for BRCA1 c.68_69del, BRCA1 c.5266dup and BRCA2 c.5946del Mutation Screen on Pap Smear Cytology Samples
Three sets of polymerase chain reaction (PCR) primers were designed for heminested PCR amplification of the target DNA fragments in the human genome which include the site of BRCA1 c.68_69del, BRCA1 c.5266dup and BRCA2 c.5946del respectively, to prepare the templates for direct Sanger sequencing scr...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4783961/ https://www.ncbi.nlm.nih.gov/pubmed/26867194 http://dx.doi.org/10.3390/ijms17020229 |
_version_ | 1782420187806433280 |
---|---|
author | Lee, Sin Hang Zhou, Shaoxia Zhou, Tianjun Hong, Guofan |
author_facet | Lee, Sin Hang Zhou, Shaoxia Zhou, Tianjun Hong, Guofan |
author_sort | Lee, Sin Hang |
collection | PubMed |
description | Three sets of polymerase chain reaction (PCR) primers were designed for heminested PCR amplification of the target DNA fragments in the human genome which include the site of BRCA1 c.68_69del, BRCA1 c.5266dup and BRCA2 c.5946del respectively, to prepare the templates for direct Sanger sequencing screen of these three founder mutations. With a robust PCR mixture, crude proteinase K digestate of the fixed cervicovaginal cells in the liquid-based Papanicolaou (Pap) cytology specimens can be used as the sample for target DNA amplification without pre-PCR DNA extraction, purification and quantitation. The post-PCR products can be used directly as the sequencing templates without further purification or quantitation. By simplifying the frontend procedures for template preparation, the cost for screening these three founder mutations can be reduced to about US $200 per test when performed in conjunction with human papillomavirus (HPV) assays now routinely ordered for cervical cancer prevention. With this projected price structure, selective patients in a high-risk population can be tested and each provided with a set of DNA sequencing electropherograms to document the absence or presence of these founder mutations in her genome to help assess inherited susceptibility to breast and ovarian cancer in this era of precision molecular personalized medicine. |
format | Online Article Text |
id | pubmed-4783961 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-47839612016-03-14 Sanger Sequencing for BRCA1 c.68_69del, BRCA1 c.5266dup and BRCA2 c.5946del Mutation Screen on Pap Smear Cytology Samples Lee, Sin Hang Zhou, Shaoxia Zhou, Tianjun Hong, Guofan Int J Mol Sci Article Three sets of polymerase chain reaction (PCR) primers were designed for heminested PCR amplification of the target DNA fragments in the human genome which include the site of BRCA1 c.68_69del, BRCA1 c.5266dup and BRCA2 c.5946del respectively, to prepare the templates for direct Sanger sequencing screen of these three founder mutations. With a robust PCR mixture, crude proteinase K digestate of the fixed cervicovaginal cells in the liquid-based Papanicolaou (Pap) cytology specimens can be used as the sample for target DNA amplification without pre-PCR DNA extraction, purification and quantitation. The post-PCR products can be used directly as the sequencing templates without further purification or quantitation. By simplifying the frontend procedures for template preparation, the cost for screening these three founder mutations can be reduced to about US $200 per test when performed in conjunction with human papillomavirus (HPV) assays now routinely ordered for cervical cancer prevention. With this projected price structure, selective patients in a high-risk population can be tested and each provided with a set of DNA sequencing electropherograms to document the absence or presence of these founder mutations in her genome to help assess inherited susceptibility to breast and ovarian cancer in this era of precision molecular personalized medicine. MDPI 2016-02-08 /pmc/articles/PMC4783961/ /pubmed/26867194 http://dx.doi.org/10.3390/ijms17020229 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lee, Sin Hang Zhou, Shaoxia Zhou, Tianjun Hong, Guofan Sanger Sequencing for BRCA1 c.68_69del, BRCA1 c.5266dup and BRCA2 c.5946del Mutation Screen on Pap Smear Cytology Samples |
title | Sanger Sequencing for BRCA1 c.68_69del, BRCA1 c.5266dup and BRCA2 c.5946del Mutation Screen on Pap Smear Cytology Samples |
title_full | Sanger Sequencing for BRCA1 c.68_69del, BRCA1 c.5266dup and BRCA2 c.5946del Mutation Screen on Pap Smear Cytology Samples |
title_fullStr | Sanger Sequencing for BRCA1 c.68_69del, BRCA1 c.5266dup and BRCA2 c.5946del Mutation Screen on Pap Smear Cytology Samples |
title_full_unstemmed | Sanger Sequencing for BRCA1 c.68_69del, BRCA1 c.5266dup and BRCA2 c.5946del Mutation Screen on Pap Smear Cytology Samples |
title_short | Sanger Sequencing for BRCA1 c.68_69del, BRCA1 c.5266dup and BRCA2 c.5946del Mutation Screen on Pap Smear Cytology Samples |
title_sort | sanger sequencing for brca1 c.68_69del, brca1 c.5266dup and brca2 c.5946del mutation screen on pap smear cytology samples |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4783961/ https://www.ncbi.nlm.nih.gov/pubmed/26867194 http://dx.doi.org/10.3390/ijms17020229 |
work_keys_str_mv | AT leesinhang sangersequencingforbrca1c6869delbrca1c5266dupandbrca2c5946delmutationscreenonpapsmearcytologysamples AT zhoushaoxia sangersequencingforbrca1c6869delbrca1c5266dupandbrca2c5946delmutationscreenonpapsmearcytologysamples AT zhoutianjun sangersequencingforbrca1c6869delbrca1c5266dupandbrca2c5946delmutationscreenonpapsmearcytologysamples AT hongguofan sangersequencingforbrca1c6869delbrca1c5266dupandbrca2c5946delmutationscreenonpapsmearcytologysamples |